Skip to main content
. 2010 Apr 1;5(4):e9945. doi: 10.1371/journal.pone.0009945

Figure 1. 6a-P peptide prevents VEGF binding to different cell types by FACS analysis.

Figure 1

. HUVECs, fibroblasts, AsPC-1 and liposarcoma cells were subjected to FACS analysis. Cells were digested and resuspensed with 2% BSA in PBS for blocking, 0.1 µg/ml rhVEGF was incubated and present or absent with 1 (low dose) or 10 (high dose) µg/ml of the peptide for 1 h in 4°C. After cold PBS washing, the samples were incubated with VEGF antibody and secondary FITC-labeled antibody. The results show that rhVEGF binding activity is inhibited when the peptide is present (A). VEGF-Trap has been used for a positive control, inhibiting VEGF binding about 70%. The synergic result shows that the rhVEGF binding is inhibited completely when 1 µg/ml of the peptide plus 0.1 µg/ml of VEGF-Trap are present with HUVECs (B). HP165A, HP165B peptides do not inhibit binding of VEGF to HUVECs (C).